Biopharma deal-making in 2017

Drug makers in 2017 again faced many of the uncertainties and pressures experienced in 2016, including continued public and political criticism of drug pricing, and the urgency to put the patient and value-based health care at the forefront of medicine…

Para acessar a publicação na íntegra clique aqui

Fonte: NATURE REVIEWS | DRUG DISCOVERY VOLUME 17 | FEBRUARY 2018 | 91